BioPorto Reports Mixed Q2 2026 Results Amid Strategic Pivot — BioPorto A/S

Event summary

BioPorto reported Q2 2026 revenue of DKK 6.9 million, down 35% YoY, but underlying NGAL revenue grew 34% at constant exchange rates, excluding recall impact.
The company completed the divestment of its antibody business to Janel Life Sciences, resulting in a net gain of DKK 53.8 million.
BioPorto advanced its U.S. regulatory pathway for the adult segment, expanding a validation study to 900 patients, pushing FDA clearance to mid-2028.
Adjusted EBITDA loss narrowed to DKK 16.3 million, an 11% improvement YoY, but still in line with expectations.
Cash position improved to DKK 75.6 million as of June 30, 2026, up from DKK 54.9 million at year-end 2025.

The big picture

BioPorto's Q2 2026 results reflect a strategic pivot toward its core NGAL platform, following the divestment of its antibody business. The company's focus on the U.S. AKI market comes amid evolving clinical guidelines and regulatory feedback, positioning it for long-term growth despite near-term financial challenges. The expanded validation study and hospital onboarding efforts highlight BioPorto's commitment to strengthening its market position in a competitive diagnostics landscape.

What we're watching

Regulatory Timeline: Whether BioPorto can maintain its expanded validation study timeline and secure FDA clearance for the adult segment by mid-2028.
Commercial Execution: The pace at which BioPorto can onboard new U.S. hospitals and sustain NGAL revenue growth amid competitive pressures.
Financial Discipline: How BioPorto balances its adjusted EBITDA loss reduction with continued investment in core NGAL platform development.